BridgeBio Pharma (BBIO) earnings, Aug 10, 2026: EPS +18%, stock −1.1%
In brief
BridgeBio Pharma reported on Aug 10, 2026. Earnings per share changed +18% year over year, 35.5% below the estimate; revenue +120%. The stock opened with a +2.8% gap and closed the day −1.1% (Aug 11, 2026). The stock is now 20.5% below its 52-week high, +18.5% over 12 months. Next report: Feb 25, 2027.
EPS vs estimate−35.5%
EPS, YoY+18%
Revenue, YoY+120%
Gap · day+2.8% · −1.1%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| May 7, 2026 | −1.4% | −0.1% |
| Aug 10, 2026 | +2.8% | −1.1% |
Next-quarter estimates, ratings and the BBIO chart are in the terminal.
Open the terminalFAQ
When is BridgeBio Pharma's next earnings report?
Feb 25, 2027. The date comes from daily data and is corrected if the company moves it.
How did BridgeBio Pharma stock react to the report?
Opening gap +2.8%, day's result −1.1%.
Did BridgeBio Pharma's earnings grow?
Earnings per share rose 18% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.